ESUR prostate MR guidelines 2012 (Q24620926)

1

0 references

Jonathan Richenberg

2

0 references

Richard Clements

3

0 references

Sadhna Verma

5

0 references

Geert Villeirs

6

0 references

Olivier Rouviere

7

0 references

Vibeke Logager

8

0 references

Jurgen J Fütterer

Prospective Assessment of Prostate Cancer Aggressiveness Using 3-T Diffusion-Weighted Magnetic Resonance Imaging–Guided Biopsies Versus a Systematic 10-Core Transrectal Ultrasound Prostate Biopsy Cohort

9

0 references

language of work or name

English

0 references

publication date

April 2012

0 references

published in

European Radiology

0 references

volume

22

0 references

issue

4

0 references

page(s)

746-57

0 references

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

7 April 2017

Cancer statistics, 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Relationship between apparent diffusion coefficients at 3.0-T MR imaging and Gleason grade in peripheral zone prostate cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Areas Suspicious for Prostate Cancer: MR–guided Biopsy in Patients with at Least One Transrectal US-guided Biopsy with a Negative Finding—Multiparametric MR Imaging for Detection and Biopsy Planning

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: recommendations from a European consensus meeting

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Is apparent diffusion coefficient associated with clinical risk scores for prostate cancers that are visible on 3-T MR images?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostate Cancer: Differentiation of Central Gland Cancer from Benign Prostatic Hyperplasia by Using Diffusion-weighted and Dynamic Contrast-enhanced MR Imaging

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Diffusion-weighted MRI at 3 T for the evaluation of prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Role of MRI in follow-up after focal therapy for prostate carcinoma

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Imaging of prostate cancer local recurrences: why and how?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Focal treatment or observation of prostate cancer: pretreatment accuracy of transrectal ultrasound biopsy and T2-weighted MRI.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Is it time to consider a role for MRI before prostate biopsy?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostate cancer: apparent diffusion coefficient map with T2-weighted images for detection--a multireader study

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Correlation of diffusion-weighted magnetic resonance data with cellularity in prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Active surveillance for prostate cancer: trials and tribulations

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

The diagnostic accuracy of CT and MRI in the staging of pelvic lymph nodes in patients with prostate cancer: a meta-analysis

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Multiparametric magnetic resonance imaging in prostate cancer: present and future

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Active surveillance for favorable risk prostate cancer: what are the results, and how safe is it?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Assessment of biologic aggressiveness of prostate cancer: correlation of MR signal intensity with Gleason grade after radical prostatectomy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

MR imaging of the prostate: 1.5T versus 3T.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Active surveillance; a reasonable management alternative for patients with prostate cancer: the Miami experience

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Dynamic contrast enhanced MRI in prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostate cancer localization with dynamic contrast-enhanced MR imaging and proton MR spectroscopic imaging

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Active surveillance for prostate cancer: for whom?

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostatic biopsy directed with endorectal MR spectroscopic imaging findings in patients with elevated prostate specific antigen levels and prior negative biopsy findings: early experience

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostate cancer: correlation of MR imaging and MR spectroscopy with pathologic findings after radiation therapy-initial experience

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Active surveillance with selective delayed intervention using PSA doubling time for good risk prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Dynamic magnetic resonance imaging of tumor perfusion. Approaches and biomedical challenges

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Endorectal magnetic resonance imaging and spectroscopy for the detection of tumor foci in men with prior negative transrectal ultrasound prostate biopsy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Patients with a history of elevated prostate-specific antigen levels and negative transrectal US-guided quadrant or sextant biopsy results: value of MR imaging

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Cancer burden in the year 2000. The global picture

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Fast dynamic gadolinium-enhanced MR imaging of urinary bladder and prostate cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

A review of normal tissue hydrogen NMR relaxation times and relaxation mechanisms from 1-100 MHz: dependence on tissue type, NMR frequency, temperature, species, excision, and age.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Clinical evidence for and implications of the multistep development of prostate cancer

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

An Exploratory Study of Endorectal Magnetic Resonance Imaging and Spectroscopy of the Prostate as Preoperative Predictive Biomarkers of Biochemical Relapse After Radical Prostatectomy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prediction of prostate cancer recurrence using magnetic resonance imaging and molecular profiles

30 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Prostate cancer detection with 3 T MRI: comparison of diffusion-weighted imaging and dynamic contrast-enhanced MRI in combination with T2-weighted imaging

30 May 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Apparent diffusion coefficient values in peripheral and transition zones of the prostate: comparison between normal and malignant prostatic tissues and correlation with histologic grade

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Clinical utility of apparent diffusion coefficient (ADC) values in patients with prostate cancer: Can ADC values contribute to assess the aggressiveness of prostate cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

A qualitative approach to combined magnetic resonance imaging and spectroscopy in the diagnosis of prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Fast acquisition-weighted three-dimensional proton MR spectroscopic imaging of the human prostate

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Usefulness of diffusion-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging in the diagnosis of prostate transition-zone cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Combined magnetic resonance imaging and spectroscopy in the assessment of high grade prostate carcinoma in patients with elevated PSA: a single-institution experience of 356 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

[Which imaging methods should be used prior to salvage radiotherapy after prostatectomy for prostate cancer?].

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Feasibility of 3T dynamic contrast-enhanced magnetic resonance-guided biopsy in localizing local recurrence of prostate cancer after external beam radiation therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Discrimination of prostate cancer from normal peripheral zone and central gland tissue by using dynamic contrast-enhanced MR imaging

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Value of diffusion-weighted imaging for the prediction of prostate cancer location at 3T using a phased-array coil: preliminary results.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Prostate cancer: sextant localization with MR imaging, MR spectroscopy, and 11C-choline PET/CT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Prostate depiction at endorectal MR spectroscopic imaging: investigation of a standardized evaluation system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Endorectal MR imaging and MR spectroscopic imaging for locally recurrent prostate cancer after external beam radiation therapy: preliminary experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Use of MRI and spectroscopy in evaluation of external beam radiotherapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Reproducibility of image interpretation in MRI of the prostate: application of the sextant framework by two different radiologists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

Prostate cancer: 1HMRS-DCEMR at 3T versus [(18)F]choline PET/CT in the detection of local prostate cancer recurrence in men with biochemical progression after radical retropubic prostatectomy (RRP)

21 January 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Magnetic resonance spectroscopic imaging (1H-MRSI) and dynamic contrast-enhanced magnetic resonance (DCE-MRI): pattern changes from inflammation to prostate cancer.

28 November 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3297750

Accurate estimation of pharmacokinetic contrast-enhanced dynamic MRI parameters of the prostate

28 November 2018

1 reference

12 December 2020

Dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) is a useful modality for the precise detection and staging of early prostate cancer

1 reference

12 December 2020

Negative prostatic biopsies in patients with a high risk of prostate cancer. Is the combination of endorectal MRI and magnetic resonance spectroscopy imaging (MRSI) a useful tool? A preliminary study

1 reference

12 December 2020

Active surveillance for good risk prostate cancer: rationale, method, and results

1 reference

12 December 2020

Comparison of the incidence of latent prostate cancer detected at autopsy before and after the prostate specific antigen era

1 reference

12 December 2020

Dynamic Contrast Enhanced, Pelvic Phased Array Magnetic Resonance Imaging of Localized Prostate Cancer for Predicting Tumor Volume: Correlation With Radical Prostatectomy Findings

1 reference

12 December 2020

Prostate cancer screening: the clinical value of diffusion-weighted imaging and dynamic MR imaging in combination with T2-weighted imaging

1 reference

12 December 2020

Standardized threshold approach using three-dimensional proton magnetic resonance spectroscopic imaging in prostate cancer localization of the entire prostate

1 reference

12 December 2020

Prostate dynamic contrast-enhanced MRI with simple visual diagnostic criteria: is it reasonable?

1 reference

12 December 2020

Combined T2-Weighted and Diffusion-Weighted MRI for Localization of Prostate Cancer

1 reference

12 December 2020

Dynamic Contrast-Enhanced Magnetic Resonance Imaging for Localization of Recurrent Prostate Cancer After External Beam Radiotherapy

1 reference

12 December 2020

Role of Dynamic Contrast-Enhanced Magnetic Resonance (MR) Imaging and Proton MR Spectroscopic Imaging in the Detection of Local Recurrence after Radical Prostatectomy for Prostate Cancer

1 reference

12 December 2020

Potential of magnetic resonance spectroscopic imaging in predicting absence of prostate cancer in men with serum prostate-specific antigen between 4 and 10 ng/ml: a follow-up study

1 reference

12 December 2020

[Pelvic MRI at 3.0 Tesla]

1 reference

12 December 2020

Magnetic resonance imaging guided prostate biopsy in men with repeat negative biopsies and increased prostate specific antigen

1 reference

12 December 2020

Accuracy of multiparametric magnetic resonance imaging in detecting recurrent prostate cancer after radiotherapy

1 reference

12 December 2020

A Study of Diffusion-Weighted Magnetic Resonance Imaging in Men with Untreated Localised Prostate Cancer on Active Surveillance

1 reference

12 December 2020

Magnetic Resonance Spectroscopic Imaging (1H-MRSI) and Dynamic Contrast-Enhanced Magnetic Resonance (DCE-MRI): Pattern Changes From Inflammation to Prostate Cancer

1 reference

https://api.crossref.org/works/10.1007/S00330-011-2377-Y

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1007/S00330-011-2377-Y

1 reference

Dimensions Publication ID

1041692485

0 references

1 reference

1 reference

PubMed publication ID

22322308

1 reference